A pilot study to assess the use of the gonadotrophin antagonist cetrorelix in preserving ovarian function during chemotherapy
A pilot study to assess the use of the gonadotrophin antagonist cetrorelix in preserving ovarian function during chemotherapy
复制标题
DOI：
10.1111/j.1479-828x.2011.01346.x
复制
发表时间：
2011-10-01
影响因子：
1.7
通讯作者：
Stern, Catharyn J.
中科院分区：
文献类型：
--
作者：
Whitehead, Julie;Toledo, Manuela G.;Stern, Catharyn J.
环磷酰胺治疗可导致卵巢早衰。这项初步研究评估了促性腺激素释放激素（GnRH）拮抗剂西曲瑞克在18-35岁女性环磷酰胺化疗期间对卵巢功能的保护作用。主要指标为化疗前、化疗后6个月和12个月时的血清促卵泡激素（FSH）和卵泡刺激素。次要结局是激素抑制作用和副作用特征的证据。
Cyclophosphamide treatment can cause premature ovarian failure. This pilot study evaluates the protective effect of the gonadotrophin releasing hormone (GnRH) antagonist, cetrorelix, on ovarian function, when used during cyclophosphamide chemotherapy in women aged 18-35. Primary outcomes measured were serum follicle stimulating hormone (FSH) and inhibin prior to and at 6 and 12 months after chemotherapy. Secondary outcomes were hormonal evidence of a suppressive effect and the side effect profile.